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Abstract
Background: Gap junctional intercellular communication (GJIC) is typically decreased in malignant tumors. Gap
junction is not presented between hematopoietic cells but occurred in bone marrow stromal cells (BMSCs). Connexin
43 (Cx43) is the major gap junction (GJ) protein; our previous study revealed that Cx43 expression and GJIC were
decreased in acute leukemic BMSCs. All-trans retinoic acid (ATRA) increases GJIC in a variety of cancer cells and has
been used to treat acute promyelocytic leukemia, but the effects of ATRA on leukemic BMSCs is unknown. In this
study, we evaluated the potential effects of ATRA on cell cycle, proliferation, and apoptosis of leukemic BMSCs. Effects
of ATRA on Cx43 expression and GJIC were also examined.
Methods: Human BMSCs obtained from 25 patients with primary acute leukemia, and 10 normal healthy donors were
cultured. Effects of ATRA on cell cycle, cell proliferation, and apoptosis were examined with or without co-treatment with
amphotericin-B. Cx43 expression was examined at both the mRNA and protein expression levels. GJIC was examined by
using a dye transfer assay and measuring the rate of fluorescence recovery after photobleaching (FRAP).
Results: ATRA arrested the cell cycle progression, inhibited cell growth, and increased apoptosis in leukemic BMSCs. Both
Cx43 expression and GJIC function were increased by ATRA treatment. Most of the observed effects mediated by ATRA
were abolished by amphotericin-B pretreatment.
Conclusions: ATRA arrests cell cycle progression in leukemic BMSCs, likely due to upregulating Cx43 expression and
enhancing GJIC function.
Keywords: All-trans retinoic acid, Bone marrow stromal cells, Connexin 43, Gap junctional intercellular communication,
Leukemia BMSCs
Background
Gap junctions (GJs) are specialized structures consisting
of highly conserved trans-membrane proteins connexins
and allow passage of small molecule (<1 kD) between
the cytoplasm of two adjacent cells [1, 2]. A total of 21
human connexin subtypes have been identified up to
date, with each one displaying unique tissue expression
pattern [3]. Decreased expression of connexins and thus
compromised gap junctional intercellular communication
(GJIC) is noted in a variety of malignant tumors and con-
tributes to their uncontrolled proliferation [1, 3–5]. In-
creased connexin expression and restored GJIC using
molecular approach have been shown to inhibit the
growth of solid tumors [6–9], decrease invasive potential,
and jeopardize neovascularization [10, 11].
GJs do not exist between hematopoietic cells but are
present between bone marrow stromal cells (BMSCs)
and hematopoietic cells [12, 13]. Communication between
BMSCs and hematopoietic cells is an important part of
the microenvironment for establishment and growth of
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tumor cells [14–16]. For GJs at these sites, connexin
43 (Cx43) is the major subtype [12]. Functional GJIC
in BMSCs has direct impact on the proliferation and
differentiation of hematopoietic stem/progenitor cells
[17]. Our previous studies revealed decreased Cx43 ex-
pression and GJIC function of acute leukemic BMSCs,
which could recover after adopting effective chemo-
therapy or transfection with Cx43 gene [18, 19]. These
findings suggested that Cx43 expression and GJIC
function in BMSCs are likely to be a dynamic process
and regulated by many factors in vivo and in vitro. This hy-
pothesis has been verified by some studies which demon-
strated that some hormones, cytokines, and drugs could
affect the expression of Cxs between coupling cells [20–23].
All-trans retinoic acid (ATRA) is a natural derivative
of vitamin A and could regulate various physiological
events, including cell cycle, embryonic development,
and cellular differentiation [24]. ATRA could inhibit
malignant transformation and produce anti-proliferative ef-
fect in several types of tumor cells, possibly through enhan-
cing GJIC function in tumor cells [25–27]. ATRA has been
used in the treatment of acute promyelocytic leukemia
(APL) [28] and other hematologic diseases [29, 30] based
on induction of differentiation and inhibition of growth.
However, whether ATRA affects GJIC in leukemic BMSCs
remains unknown.
In this study, we examined the potential effects of ATRA
on cell cycle progression of leukemic BMSCs from 25 pa-
tients with acute leukemia. Increased Cx43 expression by
ATRA was verified with mRNA and Western blot. En-
hanced GJIC function was verified with fluorescent dye
dispersion as well as a bleaching assay. The experiments
revealed arrested cell cycle progression, inhibited growth,
and increased apoptosis upon ATRA exposure. These
findings suggest that GJIC function is implicated in the
therapeutic action of ATRA for leukemia.
Results
ATRA increases Cx43 mRNA
Quantitative reverse transcription polymerase chain reac-
tion (qRT-PCR) analysis showed that treatment with ATRA
(10 uM) increased Cx43 mRNA levels in leukemic BMSCs
by >50 % (p < 0.01) to a level closed to normal BMSCs
(p < 0.05, Fig. 1). Pretreatment with amphotericin-B did
not affect the ATRA action on Cx43 mRNA.
ATRA increases Cx43 protein expression
Western blot analysis showed that ATRA (10 uM)
increased Cx43 protein levels by approximately 70 %
(p < 0.01) to a level not statistically different from nor-
mal BMSCs (Fig. 2a, b). Moreover, treatment with
amphotericin-B did not affect Cx43 protein expression
levels mediated by ATRA.
ATRA enhances GJIC
Dye transfer assay was a rapid, sensitive method to detect
GJIC function between cells [31]. In this study, Lucifer yel-
low (LY) fluorescence in leukemic BMSCs dispersed to
Fig. 1 Effects of ATRA and amphotericin-B pretreatment on Cx43 mRNA level in leukemic BMSCs. Cx43 mRNA (normalized against β-actin) was
1.53 ± 0.14 in healthy controls (N = 10), 0.56 ± 0.07 leukemic BMSCs (N = 10) treated with DMSO, 1.21 ± 0.36 in leukemic BMSCs (N = 25) exposed
to ATRA (10 uM), and 1.17 ± 0.196 in leukemic BMSCs exposed to ATRA + amphotericin-B. Data are presented as mean ± SD. Double asterisks
indicate P < 0.01
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only 1–2 cell lines surrounding the wounded edge (Fig. 3a).
After ATRA treatment, LY fluorescence dispersed to 4–5
cell lines (Fig. 3b). Pretreatment with AB could block the
effect mediated by ATRA (Fig. 3c).
The fluorescence recovery after photobleaching
(FRAP) assay showed 20 % recovery of fluorescent signal
in leukemic BMSCs at 1 min after photobleaching. The
maximal recovery percentage was 36.25 % (±2.14); the
average recovery rate was 4.82 % (±0.78) min−1 (Fig. 4d–f).
ATRA treatment promoted the recovery of fluores-
cent signal after photobleaching (Fig. 4a–c): 35 % of
cells could be recovered in 1 min and 80.94 %
(±1.46) could be recovered within 30 min. The aver-
age recovery rate was increased to 15.03 % (±1.27)
min−1 (Fig. 4g, h). Pretreatment with amphotericin-B
blocked the effects of ATRA.
ATRA changes biologic characteristics of BMSCs through
GJIC
ATRA (10 uM for 48 h) inhibited the cell growth of
leukemic BMSCs by 40 % (p < 0.05; Fig. 5), and pretreat-
ment with amphotericin-B blocked the ATRA effects.
Flow cytometric analysis showed that ATRA treatment
led to decrease the percentage of the cells in S phase from
29.5 to 7.96 % and led to increase the percentage of cells in
the G0/G1 phase from 61.1 to 77.2 % (Additional file
1: Figure S1A–C). Such effects were abolished by
amphotericin-B pretreatment (Fig. 6).
Fig. 2 Effects of ATRA and amphotericin-B pretreatment on Cx43 protein level in leukemic BMSCs. a Cx43 protein (normalized against β-actin)
was 1.35 ± 0.17 in healthy controls (N = 10), 0.37 ± 0.02 in leukemic BMSCs (N = 25) treated with DMSO, 1.15 ± 0.03 in leukemic BMSCs exposed to
ATRA (10 uM) (N = 25), and 1.07 ± 0.02 in leukemic BMSCs treated with both ATRA and amphotericin-B (N = 25); b relative normalization gray level
of Cx43 Western blotting band in health controls, leukemic BMSCs, leukemic BMSCs + ATRA, leukemic BMSCs + ATRA + AB. Data are presented as
mean ± SD. Double asterisks indicate P < 0.01
Liu et al. Journal of Hematology & Oncology  (2015) 8:110 Page 3 of 9
ATRA treatment increased apoptosis rate from 5.16 ±
2.35 to 9.78 ± 4.88 % (p < 0.05) (Additional file 2: Figure
S2A–C). Such effects were attenuated by amphotericin-
B pretreatment (p < 0.05; Fig. 7).
Discussion
Abnormal expression of connexin genes in tumor cells is
the result of downregulation rather than genomic dele-
tion or mutation, and thus could be rescued by pharma-
cological treatment [32, 33]. Increasing the expression of
connexin genes could restore the function of gap junc-
tions [3, 34]. Recent studies showed that ATRA could
improve GJIC function in several types of tumor cells
[28, 35].
In the current study, we extended previous findings to
leukemic BMSCs. ATRA treatment increased the expres-
sion of Cx43 at both mRNA and protein levels and
resulted in increased intercellular communication. The
mechanisms of such action remain obscure, but based
on the secondary structure of Cx43 [36, 37], it is reason-
able to speculate that ATRA could bind to retinoic acid
nuclear receptors (i.e., RARs and RXRs) and activate the
PKC pathways, which in turn phosphorylate proteins
that bind to the phosphorylation site of the Cx43 mRNA.
The resulting instability due to AQUA repeated sequences
decrease the degradation of Cx43 mRNA. Alternatively,
ATRA could activate Cx43 gene transcription and transla-
tion more directly through binding to factors such as AP-1.
In a previous study from this laboratory [18], we
demonstrated that GJIC function is dysfunctional be-
tween leukemic BMSCs. Such a finding is consistent
with the reported decrease in GJIC in several solid tu-
mors [8, 38, 39]. In the current study, we showed that
GJIC between leukemic BMSCs is enhanced by ATRA
treatment. It is noteworthy to mention the discrepancy
of the reported action of ATRA on connexin gene ex-
pression in tumors in previous studies. For example,
Wageenblatt et al. [40] reported inhibited expression
of several connexin genes, including Cx43, by ATRA in
carcinoma of urinary bladder. Based on such a finding,
the authors argued that connexin gene upregulation
provides a “growth advantage” in certain type(s) of
tumor cells.
The results of the current study clearly showed that
ATRA could arrest cell cycle progression in leukemic
BMSCs. Consistently, cell proliferation was decreased
and apoptosis was enhanced. These effects could be abol-
ished by amphotericin-B pretreatment, and thus could
reasonably attributed to GJICs.
The connection between increased GJIC and BMSC
biological properties is now unknown. Potential mecha-
nisms could include purinergic signaling via extracellular
Fig. 3 Effects of dye transfer between BMSCs by using laser confocal microscopy. a Leukemic BMSCs not exposed to ATRA; b leukemic BMSCs
exposed to ATRA (10 M); c leukemic BMSCs treated with both ATRA and amphotericin-B. Scale bar = 50 um
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adenosine triphosphate (ATP), change of Ca2+ internal
flow from extracellular through gap junction, and down-
regulation of monocyte chemotactic protein 1 expres-
sion [41–44]. Nevertheless, the current study extended
previous findings of ATRA in solid tumors [11, 45] to
leukemia.
Conclusions
ATRA treatment could arrest cell cycle progression in
leukemic BMSCs, likely due to increasing Cx43 expres-
sion and enhancing GJICs in human leukemic BMSCs.
These findings encourage future exploration of using
ATRA in the treatment of hematopoietic malignancies.
Materials
Sample source
Samples of acute leukemic bone marrow were obtained
from 25 patients with primary acute leukemia from the
Department of Hematology of Xinqiao Hospital between
April 2014 and February 2015. Patients included 14
males and 11 females, with a median age of 33. Among
the patients were 14 patients with ALL, 3 patients with
AML-M2, 3 patients with AML-M3, 3 patients with
AML-M5, and 2 patients with AML-M6. The diagnosis
was established on the basis of clinical data, tissue/cell
morphology, and immunophenotyping. Bone marrow
samples from ten normal healthy donors were used as
healthy controls. The research was approved by the Ethics
Fig. 4 FRAP assay in BMSCs. a Pre-photobleaching of leukemic BMSCs exposed to ATRA; b 1.5 s post-photobleaching of leukemic BMSCs exposed
to ATRA; c 30 min post photobleaching of leukemic BMSCs exposed to ATRA. d–f Leukemic BMSCs without ATRA treatment (d pre-photobleaching of
leukemic BMSCs without ATRA treatment; e 1.5 s post-photobleaching of leukemic BMSCs without ATRA treatment; f 30 min post photobleaching of
leukemic BMSCs without ATRA treatment). g Effects of ATRA on fluorescence redistribution in leukemic BMSCs. h Effects of ATRA on GJIC in leukemic
BMSCs. Arrow symbols photobleached cells. *p < 0.01 vs. leukemic BMSCs. Images were taken under a laser confocal microscope at ×400 magnification
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Committee of Xinqiao Hospital, and all subjects gave writ-
ten informed consent.
Cell culture and treatment
Human BMSCs were isolated as described previously
[46] and were plated in T75 flasks for continuous pas-
sage in Dulbecco’s modified Eagle’s medium (DMEM)
(Gibco, USA) supplemented with 12.5 % FBS (Gibco,
USA), 12.5 % HS (Gibco, USA), and 0.1 mM hydrocorti-
sone (Sigma, USA). Medium was changed twice weekly,
and cells were passaged into fresh culture flasks at a ra-
tio of 1:4 upon reaching confluence by using trypsin
(Sigma, USA). The cultures were incubated at 37 °C in a
humidified incubator with 5 % CO2.
ATRA and amphotericin-B (both from Sigma) stock
solutions were prepared in dimethyl sulfoxide (DMSO;
Sigma, USA) and stored at −20 °C prior to use. The final
concentration of DMSO was <0.1 %. BMSCs at passage
3 (reach to 80 % confluence) were used for experiments.
qRT-PCR
Total RNA was extracted from BMSCs by using a com-
mercial kit from Stratagene (USA). cDNA synthesis and
amplification were carried out using 2 μg mRNA with
RevertAid™ First Strand cDNA Synthesis Kit (Fermentas,
USA) and GeneAmp PCR System 2700 Thermal Cycler
(Applied Biosystems, USA). qRT-PCR conditions were as
follows: 95 °C for 15 min, then 40 cycles of 94 °C for 30 s,
60 °C for 30 s, and 72 °C for 30 s. Primers were as follows:
Cx43 (NM_000165), forward 5′-AACCTGGTTGTGAAA
ATGTC-3′; reverse 5′-GCAAGTGTAAACAGCACTCA-
3′; β-actin (NM_001101), forward 5′-CCTGTGGCATC
CACGAAACT-3′; reverse 5′-GAGCAATGATCCTGATC
TTC-3′. Results were normalized against β-actin.
Western blot
Western blot analysis was performed using whole-cell
extract. Protein concentration of the samples was deter-
mined using a BCA method. Proteins (20 μg per lane)
were separated using 12 % SDS-PAGE gel, transferred to
nitrocellulose membrane, and blocked with 5 % skim
milk in PBS. The membrane was incubated with a rabbit
polyclonal anti-Cx43 antibody (Sigma, USA), and then
Fig. 5 Effects of ATRA on the cell viability of BMSCs (MTT assay). Cell
viability was evaluated by MTT assay in leukemic BMSCs, leukemic BMSCs
treated with ATRA, and leukemic BMSCs treated with both ATRA and
amphotericin-B. Data are presented as mean ± SD. Single asterisk
indicates significant difference (P < 0.05)
Fig. 6 Effects of ATRA on the cell cycle (FCM assay). Cell cycle was
examined with FCM assay in leukemic BMSCs, leukemic BMSCs treated
with ATRA, and leukemic BMSCs treated with both ATRA and
amphotericin-B. Data are presented as mean ± SD. Single asterisk
indicates significant difference (P < 0.05)
Fig. 7 Effects of ATRA on the apoptosis of BMSCs (FCM assay). Cell
apoptosis was examined with FCM assay in leukemic BMSCs, leukemic
BMSCs treated with ATRA, and leukemic BMSCs treated with both ATRA
and amphotericin-B. Data are presented as mean ± SD. Single asterisk
indicates significant difference (P< 0.05)
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with a secondary antibody linked to horseradish peroxid-
ase prior to ECA visualization (Amersham Biosciences
AB, Uppsala, Sweden). Blots were washed, reprobed with
an anti-GAPDH antibody (Sigma, USA), and then devel-
oped in an identical manner for assessment of GAPDH
to ensure even loading.
Dye transfer assay
Transfer assay was carried out as previously described
[47]. Briefly, cultured cells were rinsed thoroughly with
Hanks’ balanced salt solution (HBSS) (with calcium and
magnesium) containing 1 % BSA. A 27-gauge needle was
used to create multiple scratches (minimum distance
between scratches 1 cm) in the cell monolayer in the pres-
ence of PBS containing 0.5 % Lucifer yellow (Gibco, USA).
After exactly 1 min, the culture was rinsed with HBSS and
then incubated for 1–10 min in the saved culture medium
to allow the loaded dye to transfer to adjoining cells. The
cells were then rinsed and fixed with 4 % paraformalde-
hyde and immediately analyzed under a laser confocal
scanning microscope (LCSM; Leica, German) at 485 nm.
GJIC was defined as the average distance of dye travel
(μm) at six different sites in each sample.
FRAP assay
FRAP assay was carried out in living cells as described
previously [48]. Briefly, cells cultured on glass cover slips
were loaded with C-FDA (10 μmol/L, 15 min; Sigma) at
37 °C and washed thoroughly with DMEM medium. A
cell with direct contact with 4–5 neighboring cells within a
cluster was selected under the LCSM. A pre-bleach image
of the whole field was taken using low laser intensity
(acousto-optic tunable filter (AOTF) = 10 %, zoom= ×2).
Then, laser intensity was increased by ×50 (AOTF = 50 %,
zoom= ×20), and the target BMSCs was photobleached for
1 s. Transfer of fluorescent dye from neighboring cells was
examined by scanning at 50 s intervals for a total period of
30 min. The rate of fluorescence recovery index was calcu-
lated as: R = (It − I0) / (I − I0) × 100 %, where I0 is the inten-
sity of the photo-bleached fluorescence and I is the
intensity of pre-bleached fluorescence.
MTT assay
Cell proliferation was examined using a methyl thiazolyl
tetrazolium (MTT) assay (Sigma, USA) at 610 nm. Data
were averaged from three independent experiments.
Flow cytometry
Flow cytometry (FCM) assay was carried out as described
previously [49]. BMSCs were washed, fixed in 70 % etha-
nol, and resuspended in 10 mL PBS. Cells were stained
with propidium iodide (5 μL 10 mg/mL) and DNAse-free
RNase (200 μg/mL) for 20 min prior to FACS analysis
using a FACSVantage flow cytometer (Becton Dickinson,
USA) and analyzed by CellQuest software. At least 1 × 104
cells were analyzed for each sample.
Apoptosis
Apoptosis was determined by Annexin V-FITC (Gibco,
USA) and FCM analyses. After washing with PBS, 106
BMSCs were resuspended in binding buffer containing
Annexin V-FITC (1 mg/mL). The mixture was incubated
for 10 min in the dark under room temperature and
then analyzed with FACSVantage flow cytometer and
CellQuest software.
Statistical analysis
Data are represented as mean with standard deviation
and analyzed with Student’s t test, except for GJIC
(Pearson’s chi-squared test). Statistical significance was
set at p < 0.05.
Additional files
Additional file 1: Figure S1. The original flow plots of cell cycle in
leukemic BMSCs using FCM assay. (A) Leukemic BMSCs; (B) leukemic
BMSCs exposed to ATRA; (C) leukemic BMSCs treated with both ATRA
and amphotericin-B.
Additional file 2: Figure S2. The original flow plots of cell apoptosis in
leukemic BMSCs using FCM assay. Leukemic BMSCs were treated DMSO,
ATRA, and ATRA + AB, then cells were stained with Annexin V-FITC and
propidium iodide (PI), followed by analysis on a flow cytometer. (A)
Leukemic BMSCs; (B) leukemic BMSCs exposed to ATRA; (C) leukemic
BMSCs treated with both ATRA and amphotericin-B.
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